Sickle Cell Nephropathy Clinical Trial
Official title:
Pattern of Sickle Cell Nephropathy in Patients With Sickle Cell Disease
There are some diseases that give rise to diverse renal manifestations as does sickle cell disease
Such involvement adversely affects virtually all major physiological processes in the kidney,
and leads to complications that are common and chronic on the one hand (such as impaired
urinary concentrating ability), and those that are rare and uniformly fatal on the other
(such as renal medullary carcinoma) This steady adverse renal sequelae shortens the average
lifespan of patients with SCD.
Proteinuria and a reduced glomerular filtration rate are risk factors associated with
increased mortality among those patients with approximately 16-18% of overall mortality in
this patient group is due to kidney disease.
Once end stage renal disease is reached, the mortality of patients who are on haemodialysis
and have SCD is increased severalfold relative to the mortality of patients who are on
haemodialysis but do not have SCD.
Thus,although the average lifespan of patients with SCD has increased during recent decades
owing to improved management of complications outside the kidney,kidney disease contributes
substantially to the still increased mortality in SCD.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01732718 -
Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease
|
Phase 2 | |
| Recruiting |
NCT06065852 -
National Registry of Rare Kidney Diseases
|
||
| Recruiting |
NCT04335721 -
A Voxelotor for Sickle Cell Anemia Patients at Highest Risk for Progression of Chronic Kidney Disease
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT01891292 -
Efficacy of Antioxidant Therapy Compared With Enalapril in Sickle Nephropathy
|
N/A |